Silexion Therapeutics (SLXN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.15, -19.05% vs the prior close of $0.19.
- Volume 823.77K shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SLXN slides 19.0% to $0.15, a 52-week low. Closed at $0.15, -19.05% vs the prior close of $0.19. Day range $0.15–$0.19, opened at $0.19.
SLXN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SLXN slides 19.0% to $0.15, a 52-week low
- Closed at $0.15, -19.05% vs the prior close of $0.19. Day range $0.15–$0.19, opened at $0.19.
- Volume was 823.77K shares, 0.1x its 50-day average of 12.78M — lighter than usual.
- Price is -61.7% vs its 50-day average ($0.40) and -98.0% vs its 200-day average ($7.72).
- 52-week range $0.15–$38.19; today's close sits at 0% of that range, 99.6% below the 52-week high.
Oct 15, 2026 — SLXN jumps 10.5% to $0.19
- Closed at $0.19, +10.53% vs the prior close of $0.17. Day range $0.17–$0.19, opened at $0.17.
- Volume was 2.75M shares, 0.2x its 50-day average of 12.72M — lighter than usual.
- Price is -56.3% vs its 50-day average ($0.43) and -97.6% vs its 200-day average ($7.81).
- 52-week range $0.16–$38.20; today's close sits at 0% of that range, 99.5% below the 52-week high.
Oct 14, 2026 — SLXN dips 2.8% to $0.17, a 52-week low, 7 down days in a row
- Closed at $0.17, -2.84% vs the prior close of $0.18. Day range $0.16–$0.18, opened at $0.18.
- Volume was 704.90K shares, 0.1x its 50-day average of 12.72M — lighter than usual.
- Price is -63.2% vs its 50-day average ($0.46) and -97.8% vs its 200-day average ($7.91).
- 52-week range $0.16–$38.20; today's close sits at 0% of that range, 99.6% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — SLXN dips 1.1% to $0.18, a 52-week low, 6 down days in a row
- Closed at $0.18, -1.12% vs the prior close of $0.18. Day range $0.16–$0.19, opened at $0.19.
- Volume was 2.09M shares, 0.2x its 50-day average of 12.68M — lighter than usual.
- Price is -64.8% vs its 50-day average ($0.50) and -97.8% vs its 200-day average ($8.02).
- 52-week range $0.16–$39.40; today's close sits at 0% of that range, 99.6% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — SLXN slides 17.2% to $0.18, a 52-week low, 5 down days in a row
- Closed at $0.18, -17.21% vs the prior close of $0.22. Day range $0.18–$0.21, opened at $0.21.
- Volume was 1.27M shares, 0.1x its 50-day average of 12.66M — lighter than usual.
- Price is -66.7% vs its 50-day average ($0.53) and -97.8% vs its 200-day average ($8.14).
- 52-week range $0.18–$40.70; today's close sits at 0% of that range, 99.6% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — SLXN slides 8.5% to $0.22, a 52-week low, 4 down days in a row
- Closed at $0.22, -8.51% vs the prior close of $0.23. Day range $0.21–$0.23, opened at $0.23.
- Volume was 821.10K shares, 0.1x its 50-day average of 12.64M — lighter than usual.
- Price is -62.2% vs its 50-day average ($0.57) and -97.4% vs its 200-day average ($8.26).
- 52-week range $0.21–$40.70; today's close sits at 0% of that range, 99.5% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — SLXN slides 7.5% to $0.23, a 52-week low, 3 down days in a row
- Closed at $0.23, -7.48% vs the prior close of $0.25. Day range $0.22–$0.25, opened at $0.25.
- Volume was 1.51M shares, 0.1x its 50-day average of 12.63M — lighter than usual.
- Price is -60.9% vs its 50-day average ($0.60) and -97.2% vs its 200-day average ($8.38).
- 52-week range $0.22–$42.00; today's close sits at 0% of that range, 99.4% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — SLXN slides 3.4% to $0.25
- Closed at $0.25, -3.42% vs the prior close of $0.26. Day range $0.25–$0.26, opened at $0.25.
- Volume was 1.08M shares, 0.1x its 50-day average of 12.61M — lighter than usual.
- Price is -59.6% vs its 50-day average ($0.63) and -97.0% vs its 200-day average ($8.50).
- 52-week range $0.24–$42.00; today's close sits at 0% of that range, 99.4% below the 52-week high.
Oct 6, 2026 — SLXN dips 1.1% to $0.26
- Closed at $0.26, -1.13% vs the prior close of $0.27. Day range $0.25–$0.27, opened at $0.27.
- Volume was 999.30K shares, 0.1x its 50-day average of 12.59M — lighter than usual.
- Price is -60.9% vs its 50-day average ($0.67) and -96.9% vs its 200-day average ($8.62).
- 52-week range $0.24–$42.00; today's close sits at 0% of that range, 99.4% below the 52-week high.
Oct 5, 2026 — SLXN rises 2.3% to $0.27
- Closed at $0.27, +2.31% vs the prior close of $0.26. Day range $0.26–$0.27, opened at $0.26.
- Volume was 1.23M shares, 0.1x its 50-day average of 12.57M — lighter than usual.
- Price is -63.0% vs its 50-day average ($0.72) and -97.0% vs its 200-day average ($8.75).
- 52-week range $0.24–$42.60; today's close sits at 0% of that range, 99.4% below the 52-week high.
- SEC filings that day: DEF 14A.
Oct 2, 2026 — SLXN slides 6.8% to $0.26
- Closed at $0.26, -6.81% vs the prior close of $0.28. Day range $0.26–$0.30, opened at $0.27.
- Volume was 2.03M shares, 0.2x its 50-day average of 12.53M — lighter than usual.
- Price is -65.7% vs its 50-day average ($0.76) and -97.1% vs its 200-day average ($8.88).
- 52-week range $0.24–$42.60; today's close sits at 0% of that range, 99.4% below the 52-week high.
SLXN latest news & SEC filings
Every SEC filing by or about SLXN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 29, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Sep 28, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Sep 25, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 16, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Sep 9, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 24, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Aug 19, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 18, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade SLXN
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 18, 2026, Nov 12, 2025, Aug 12, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 10.94% (largest 28.2%). That is a volatile stock.
- Liquidity: about 21.44M shares (≈$3.28M) trade per day on average.
- 52-week position: $0.15 vs a range of $0.15–$38.19 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on May 29, 2026, 1:15 on Jul 29, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Mitchell Shirvan sold 22,818 shares on Mar 26, 2026.
- Latest filings: 8-K Sep 30, 2026; 8-K Sep 29, 2026; 8-K Sep 28, 2026.
- Share count: 5.56M shares outstanding (Aug 13, 2026), +660.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SLXN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.19 | 0.19 | 0.15 | 0.15 | 823.77K |
| Oct 15, 2026 | 0.17 | 0.19 | 0.17 | 0.19 | 2.83M |
| Oct 14, 2026 | 0.18 | 0.18 | 0.16 | 0.17 | 704.90K |
| Oct 13, 2026 | 0.19 | 0.19 | 0.16 | 0.18 | 2.09M |
| Oct 12, 2026 | 0.21 | 0.21 | 0.18 | 0.18 | 1.27M |
| Oct 9, 2026 | 0.23 | 0.23 | 0.21 | 0.22 | 821.10K |
| Oct 8, 2026 | 0.25 | 0.25 | 0.22 | 0.23 | 1.51M |
| Oct 7, 2026 | 0.25 | 0.26 | 0.25 | 0.25 | 1.08M |
| Oct 6, 2026 | 0.27 | 0.27 | 0.25 | 0.26 | 999.30K |
| Oct 5, 2026 | 0.26 | 0.27 | 0.26 | 0.27 | 1.23M |
| Oct 2, 2026 | 0.27 | 0.30 | 0.26 | 0.26 | 2.03M |
| Oct 1, 2026 | 0.26 | 0.29 | 0.25 | 0.28 | 3.30M |
| Sep 30, 2026 | 0.26 | 0.28 | 0.26 | 0.28 | 11.70M |
| Sep 29, 2026 | 0.32 | 0.40 | 0.30 | 0.32 | 256.57M |
| Sep 28, 2026 | 0.26 | 0.28 | 0.24 | 0.25 | 77.40M |
| Sep 25, 2026 | 0.24 | 0.27 | 0.24 | 0.26 | 1.17M |
| Sep 24, 2026 | 0.27 | 0.28 | 0.25 | 0.26 | 2.36M |
| Sep 23, 2026 | 0.34 | 0.38 | 0.30 | 0.31 | 8.35M |
| Sep 22, 2026 | 0.49 | 0.50 | 0.33 | 0.39 | 32.53M |
| Sep 21, 2026 | 0.42 | 0.63 | 0.41 | 0.54 | 20.13M |
About Silexion Therapeutics
Silexion Therapeutics (SLXN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in RAMAT GAN, Israel. State of incorporation: Cayman Islands. Fiscal year ends December 31. SEC CIK 2022416.
SLXN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dror Yosef Abramov | Director | Feb 23, 2026 |
| Ruth Alon | Director | Feb 23, 2026 |
| Ilan Hadar | Chairman and CEO | Jun 8, 2026 |
| Ilan Levin | Director | Jan 27, 2026 |
| Avner Lushi | Director | Feb 23, 2026 |
| Shlomo Noy | Director | Feb 25, 2026 |
| Amnon Peled | Director | Feb 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ilan Hadar | Chairman and CEO | Jun 8, 2026 |
| Hadar Mirit Horenshtein | CFO and Secretary | Jun 8, 2026 |
| Mitchell Shirvan | CSO and CDO | Jun 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
SLXN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-11.91M | 8.96 | $-10.82M |
| Dec 31, 2024 | — | $-16.52M | 394.94 | $-8.40M |
| Dec 31, 2023 | — | $-5.11M | 44.23 | $-4.53M |
Latest balance sheet: total assets $4.25M, total liabilities $4.20M, cash $2.23M (as of Jun 30, 2026).
SLXN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $0.42 |
| May 18, 2026 | 8-K Item 2.02 (results) | $2.74 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $29.10 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $72.50 |
| May 13, 2025 | 8-K Item 2.02 (results) | $145.50 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $187.50 |
| Jan 14, 2025 | 8-K Item 2.02 (results) | $265.50 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $33.60 |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SLXN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.